

Government of the People's Republic of Bangladesh
Directorate General of Drug Administration
Aushadh Vaban
Mohakhali, Dhaka-1212, Bangladesh

List of Discontinue Clinical Trial

SL	Name of the protocol	Principal Investigator Name with institute	Approval date	Discontinue date	Reasons
1.	A Phase 1 Randomized, Double-Blinded, Placebo-controlled, Dose-Escalation Study to Assess the Safety, Tolerability and Immunogenicity of Live Attenuated, Oral Shigella WRSSI Vaccine in Bangladeshi Toddlers (12 to 24 months old)	Dr. Rubhana Raqib Senior Scientist Infectious Diseases Division icddr,b	11.01.2017	Discontinued by the PI and sponsor. Informed to DGDA: 10.09.2017	After the study was initiated, its funder, the Bill and Melinda Gates Foundation (BMGF) made significant changes to the PATH Enteric Vaccine Initiative (EVI) portfolio and decided not to support the three higher-dose cohorts planned as part of this study.
2.	Bioequivalence study of Olaparib tablets 2 x 150 mg of Cdila Healthcare ltd,India and LYNPARA®(Olaparib) Tablets 2 x 150 mg of AstraZeneca Pharmaceuticals LP, in 16 female ovarian cancer and metastatic breast cancer under fed conditions	Dr.Kamrun Nahar Liza MBBS,MPH Deputy Asst.Director (Medical Services) Ahsania Mission Cancer and General Hospital.	23.12.2020	Discontinued by the PI and sponsor. Informed to DGDA: 16.05.2021	Due to one mentioned inclusion criteria in the protocol is subject should be BRCA positive, PI failed to enroll any subject within time and by this time IP of the study will be expired. Sponsor is not ready to increase the timeline and budget of the trial.